1 of 1
Story summary
- BioNTech co-founders Ugur Sahin and Özlem Türeci will leave by the end of 2026 to launch a startup focused on next-generation mRNA technology.
- BioNTech will grant rights to its mRNA technology to the new venture for a minority stake.
- The move follows declining COVID-19 vaccine sales and a shift to oncology.
- BioNTech will maintain its drug development pipeline while collaborating with the new startup on future therapies.
